8-K: Monopar Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Monopar Therapeutics reports its Q4 and full-year 2024 financial results, highlighting progress with ALXN1840 and MNPR-101 programs, and a strengthened balance sheet.

Summary

• Monopar Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company in-licensed ALXN1840, initiated two Phase 1 clinical trials for radiopharmaceuticals, and raised over $55 million through financings in 2024.
• Monopar plans to submit an NDA for ALXN1840 for Wilson disease in early 2026.
• The company initiated a Phase 1a clinical trial for MNPR-101-Lu in patients with advanced cancers and dosed the first patient in December 2024.
• Encouraging imaging and dosimetry data for MNPR-101-Zr were presented at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress.
• In Q4 2024, Monopar raised over $55 million through a public offering and private placement.
• Cash, cash equivalents, and short-term investments as of December 31, 2024, were $60.2 million.
• Monopar expects current funds to be sufficient to continue operations at least through December 31, 2026.
• Net loss for the fourth quarter of 2024 was $10.9 million, or $2.23 per share, compared to $1.8 million, or $0.60 per share, for the fourth quarter of 2023.
• Net loss for the year ended December 31, 2024, was $15.6 million, or $4.11 per share, compared to $8.4 million, or $3.04 per share, for the year ended December 31, 2023.
• R&D expenses for the fourth quarter of 2024 were $9.9 million compared to $1.0 million for the fourth quarter of 2023.
• R&D expenses for the year ended December 31, 2024, were $13.0 million compared to $5.6 million for the year ended December 31, 2023.
• G&A expenses for the fourth quarter of 2024 were $1.2 million, compared to $0.9 million for the fourth quarter of 2023.
• G&A expenses for the year ended December 31, 2024, were $3.2 million, compared to $3.2 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported increased losses, it also made significant progress in its clinical programs and strengthened its financial position through successful financings. The planned NDA submission for ALXN1840 is a positive catalyst.

Positives

• Monopar is planning to submit an NDA for ALXN1840 for Wilson disease in early 2026, indicating significant progress in this program.
• The company successfully raised over $55 million in Q4 2024, strengthening its financial position.
• Monopar's cash position of $60.2 million is expected to fund operations through December 31, 2026.
• The initiation of a Phase 1a clinical trial for MNPR-101-Lu and the dosing of the first patient in December 2024 are positive steps in the development of this therapeutic.
• Encouraging imaging and dosimetry data for MNPR-101-Zr were presented at a major industry conference.

Negatives

• The net loss for the fourth quarter of 2024 was $10.9 million, significantly higher than the $1.8 million loss in the same quarter of 2023.
• The net loss for the year ended December 31, 2024, was $15.6 million, also higher than the $8.4 million loss in 2023.
• R&D expenses increased significantly in both the fourth quarter and full year 2024, primarily due to the in-licensing of ALXN1840.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including regulatory discussions, clinical trial outcomes, and market acceptance of potential products.
• There are uncertainties related to the regulatory discussions that Monopar intends to initiate related to ALXN1840 and the outcome thereof.
• Future radiation dosimetry analytics may not be consistent with estimated data.
• Monopar may not find enough patients to successfully enroll its MNPR-101-Lu therapeutic study.
• The Phase 1 imaging and dosimetry clinical trial in advanced cancer patients with MNPR-101-Zr may not yield consistently satisfactory results.
• Future preclinical or clinical data may not be as promising as the data to date.
• MNPR-101-Zr and/or MNPR-101-Lu may cause unexpected serious adverse effects or fail to be effective against the cancer tumors in humans.
• The trials could result in a clinical hold should there be a serious adverse event.
• Monopar's ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization.

Future Outlook

Monopar expects its current funds to be sufficient to continue operations at least through December 31, 2026, to advance its programs, including filing an NDA for ALXN1840 and continuing clinical trials for MNPR-101.

Management Comments

• 2024 was a productive year for Monopar, with the in-licensing of ALXN1840, the initiation of two first-in-human radiopharma Phase 1 clinical trials, and the strengthening of our balance sheet with net proceeds of over $55 million from financings, said Chandler Robinson, MD, Chief Executive Officer of Monopar.
• We are especially grateful to the Wilson disease patients. Their testimonies and support are what provided the opportunity for Monopar to progress ALXN1840 toward an NDA filing.

Industry Context

Monopar's focus on radiopharmaceuticals and rare diseases aligns with growing interest and investment in these areas within the biopharmaceutical industry. The in-licensing of ALXN1840 from Alexion/AstraZeneca demonstrates a strategic move to acquire promising assets for rare disease treatment.

Comparison to Industry Standards

• Monopar's cash runway extending to December 2026 is relatively strong compared to other clinical-stage biotechs, providing financial flexibility.
• The increase in R&D expenses due to in-licensing is a common occurrence for companies acquiring new assets, similar to acquisitions made by companies like BioMarin or Sarepta Therapeutics.
• The planned NDA submission for ALXN1840 in early 2026 places Monopar in a similar timeline to other companies developing treatments for rare diseases, such as Ultragenyx or Horizon Therapeutics.

Stakeholder Impact

• Shareholders: The financial results and progress in clinical programs will impact shareholder value.
• Wilson disease patients: The planned NDA submission for ALXN1840 offers hope for a new treatment option.
• Cancer patients: The ongoing clinical trials for MNPR-101-Zr and MNPR-101-Lu could potentially lead to new therapies for advanced cancers.

Next Steps

• Submit an NDA with the FDA for ALXN1840 for Wilson disease in early 2026.
• Continue to conduct and conclude the first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr.
• Continue to conduct the first-in-human therapeutic clinical trial of MNPR-101-Lu.
• Advance the preclinical MNPR-101-Ac program into the clinic.
• Invest in internal research and development projects to expand its radiopharma and rare disease pipeline.

Key Dates

Keywords

Monopar Therapeutics, ALXN1840, MNPR-101, Wilson disease, Radiopharmaceutical, Clinical trials, Financial results, Net loss, R&D expenses, NDA, Financing